[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:tardive-dyskinesia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":42,"states":43},"Tardive dyskinesia",5,4,[8,16,23,29,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07365462","Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia",[12],"Phase 2","RECRUITING","2026-08-26T02:15:40.343619Z","2026-05-05T02:43:29.358440Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06997198","Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual\u002FDevelopmental Disabilities",[20],"Phase 4","2026-08-26T02:17:36.611194Z","2026-05-05T02:43:28.866290Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07105111","A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor",[20],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:27.259690Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT00001208","Botulinum Toxin for the Treatment of Involuntary Movement Disorders",[],"2026-08-26T02:18:04.640417Z","2026-07-05T18:42:10.718856Z",{"nct_id":36,"title":37,"phases":38,"status":39,"updated_at":40,"content_modified":41},"NCT06218719","Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients",[],"NOT_YET_RECRUITING","2026-08-26T02:18:31.164304Z","2026-05-13T02:55:06.426291Z",[],[44,48],{"state":45,"count":46,"slug":47},"California",3,"california",{"state":49,"count":46,"slug":50},"Ohio","ohio"]